Cumberland Pharmaceuticals (CPIX) to Release Quarterly Earnings on Tuesday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is expected to announce its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Cumberland Pharmaceuticals to announce earnings of ($0.13) per share and revenue of $8.5030 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The company had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Price Performance

CPIX stock opened at $6.68 on Friday. The firm has a market cap of $100.07 million, a P/E ratio of -13.63 and a beta of 0.09. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. Cumberland Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $8.09. The stock has a 50-day simple moving average of $6.29 and a 200-day simple moving average of $4.72.

Cumberland Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were issued a $1.50 dividend.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CPIX. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals during the second quarter valued at $34,000. Bridgeway Capital Management LLC lifted its position in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after buying an additional 4,200 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares during the period. Two Sigma Investments LP boosted its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 5,653 shares during the last quarter. 15.51% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.